Sutro Biopharma (FRA:S090) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:S090 Sutro Biopharma Inc FRA:S090
41 GF Score
Price €26.40
GF Value €10.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Notes Receivable?

Sutro Biopharma FRA:S090 +2.33% 41 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:S090 with a GF Score™ of 41/100 and a GF Value™ of €10.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Sutro Biopharma's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Sutro Biopharma Notes Receivable Related Terms

Sutro Biopharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Notes Receivable Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sutro Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:S090
41GF Score
Sutro Biopharma Inc FRA:S090
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Sutro Biopharma (FRA:S090) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Notes Receivable too high?
Sutro Biopharma's current Notes Receivable is €0.00 Mil. Overall, Sutro Biopharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Notes Receivable compare to NGNE and OCGN?
Sutro Biopharma's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.06, compared to a current price of €26.40 — trading 162.4% above its estimated fair value. The current Notes Receivable is €0.00 Mil. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (FRA:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €26.40 is trading 162.4% above its estimated GF Value™ of €10.06. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for FRA:S090:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €10.06 vs. price of €26.40 (162.4% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USA
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score

Get the complete analysis for FRA:S090

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.40
Price
€10.06
GF Value